Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic

Comorbidities in rheumatic and musculoskeletal diseases (RMDs) not only increase morbidity and mortality but also confound disease activity, limit drug usage and increase chances of severe infections or drug-associated adverse effects. Most RMDs lead to accelerated atherosclerosis and variable manif...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Sakir, Gasparyan, Armen Yuri, Zimba, Olena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778868/
https://www.ncbi.nlm.nih.gov/pubmed/33388969
http://dx.doi.org/10.1007/s00296-020-04764-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778868/
https://www.ncbi.nlm.nih.gov/pubmed/33388969
http://dx.doi.org/10.1007/s00296-020-04764-5

Ejemplares similares